Cargando…

Healthy Donors Harbor Memory T Cell Responses to RAS Neo-Antigens

SIMPLE SUMMARY: Memory T cells from healthy individuals respond to stimulation with peptides derived from cancer-specific RAS mutations, thus suggesting that healthy individuals have been challenged with RAS mutations earlier in life. ABSTRACT: The RAS mutations are the most frequently occurring som...

Descripción completa

Detalles Bibliográficos
Autores principales:	Holmström, Morten Orebo, Andersen, Mads Hald
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7589254/ https://www.ncbi.nlm.nih.gov/pubmed/33086698 http://dx.doi.org/10.3390/cancers12103045

Ejemplares similares

Cancer Immune Therapy for Philadelphia Chromosome-Negative Chronic Myeloproliferative Neoplasms
por: Holmström, Morten Orebo, et al.
Publicado: (2020)

Patients With Myeloproliferative Neoplasms Harbor High Frequencies of CD8 T Cell-Platelet Aggregates Associated With T Cell Suppression
por: Carnaz Simões, Ana Micaela, et al.
Publicado: (2022)

Corrigendum: Patients with myeloproliferative neoplasms harbor high frequencies of CD8 T cell-platelet aggregates associated with T cell suppression
por: Simões, Ana Micaela Carnaz, et al.
Publicado: (2022)

Novel Strategies for Peptide-Based Vaccines in Hematological Malignancies
por: Klausen, Uffe, et al.
Publicado: (2018)

Therapeutic cancer vaccination against mutant calreticulin in myeloproliferative neoplasms induces expansion of specific T cells in the periphery but specific T cells fail to enrich in the bone marrow
por: Holmström, Morten Orebo, et al.
Publicado: (2023)

Tumor microenvironment antigens
por: Andersen, Mads Hald
Publicado: (2022)

Revisiting Circulating Extracellular Matrix Fragments as Disease Markers in Myelofibrosis and Related Neoplasms
por: Hasselbalch, Hans Carl, et al.
Publicado: (2023)

Perspectives on interferon-alpha in the treatment of polycythemia vera and related myeloproliferative neoplasms: minimal residual disease and cure?
por: Hasselbalch, Hans Carl, et al.
Publicado: (2018)

Identification of a cyclin B1-derived CTL epitope eliciting spontaneous responses in both cancer patients and healthy donors
por: Andersen, Rikke Sick, et al.
Publicado: (2010)

Pre-existing TGF-β-specific T-cell immunity in patients with pancreatic cancer predicts survival after checkpoint inhibitors combined with radiotherapy
por: Mortensen, Rasmus Erik Johansson, et al.
Publicado: (2023)

The specific targeting of immune regulation: T-cell responses against Indoleamine 2,3-dioxygenase
por: Andersen, Mads Hald
Publicado: (2012)

The anti-apoptotic members of the Bcl-2 family are attractive tumor-associated antigens
por: thor Straten, Per, et al.
Publicado: (2010)

CD4 responses against IDO
por: Andersen, Mads Hald
Publicado: (2012)

Butyrate and propionate inhibit antigen-specific CD8(+) T cell activation by suppressing IL-12 production by antigen-presenting cells
por: Nastasi, Claudia, et al.
Publicado: (2017)

Arginase-2-specific cytotoxic T cells specifically recognize functional regulatory T cells
por: Weis-Banke, Stine Emilie, et al.
Publicado: (2022)

High frequencies of circulating memory T cells specific for calreticulin exon 9 mutations in healthy individuals
por: Holmström, Morten O., et al.
Publicado: (2019)

Characterization of T-cell responses against IκBα in cancer patients
por: Munir, Shamaila, et al.
Publicado: (2012)

The metabolic enzyme arginase-2 is a potential target for novel immune modulatory vaccines
por: Weis-Banke, Stine Emilie, et al.
Publicado: (2020)

T-cell dependent immunoselection
por: Andersen, Mads Hald
Publicado: (2012)

An arginase1- and PD-L1-derived peptide-based vaccine for myeloproliferative neoplasms: A first-in-man clinical trial
por: Grauslund, Jacob Handlos, et al.
Publicado: (2023)

Immune response to mutant neo-antigens: Cancer's lessons for aging
por: Geyer, Rory J, et al.
Publicado: (2013)

Neo-Antigen mRNA Vaccines
por: Esprit, Arthur, et al.
Publicado: (2020)

Targeting Bcl-2 stability to sensitize cells harboring oncogenic ras
por: Peng, Bo, et al.
Publicado: (2015)

Neo-antigen specific T cell responses indicate the presence of metastases before imaging
por: Fear, V. S., et al.
Publicado: (2019)

Exploitation of gamma delta T cells in cancer immunotherapy as combined antigen-presenters and cancer cell killers
por: Holmen Olofsson, Gitte, et al.
Publicado: (2014)

Sensitization of Human Pancreatic Cancer Cells Harboring Mutated K-ras to Apoptosis
por: Shen, Ling, et al.
Publicado: (2012)

Keeping each other in check: A reciprocal relationship between cytokines and miRNA
por: Andersen, Mads Hald
Publicado: (2013)

FOXP3-specific immunity
por: Andersen, Mads Hald
Publicado: (2013)

The targeting of tumor-associated macrophages by vaccination
por: Andersen, Mads Hald
Publicado: (2019)

Novel immune modulatory vaccines targeting TGFβ
por: Andersen, Mads Hald
Publicado: (2023)

Characterization of Spontaneous Immune Responses against Long Peptides Derived from Bcl-X(L) in Cancer Patients Using Elispot
por: Larsen, Stine Kiaer, et al.
Publicado: (2012)

Genomic landscape and survival analysis of ctDNA “neo-RAS wild-type” patients with originally RAS mutant metastatic colorectal cancer
por: Nicolazzo, Chiara, et al.
Publicado: (2023)

Impact of peptide:HLA complex stability for the identification of SARS-CoV-2-specific CD8(+)T cells
por: Lie-Andersen, Olivia, et al.
Publicado: (2023)

TGFβ-derived immune modulatory vaccine: targeting the immunosuppressive and fibrotic tumor microenvironment in a murine model of pancreatic cancer
por: Perez-Penco, Maria, et al.
Publicado: (2022)

A Potential Role of Indoleamine 2,3-Dioxygenase–Specific T cells in Leishmania Vaccination
por: Straten, Per thor, et al.
Publicado: (2011)

Editorial: Immunopeptidomic Approaches for the Identification of Tumor (neo)Antigens
por: Lill, Jennie R., et al.
Publicado: (2022)

A computational workflow for predicting cancer neo-antigens
por: Kasaragod, Sandeep, et al.
Publicado: (2022)

Therapeutic Cancer Vaccination With a Peptide Derived From the Calreticulin Exon 9 Mutations Induces Strong Cellular Immune Responses in Patients With CALR-Mutant Chronic Myeloproliferative Neoplasms
por: Handlos Grauslund, Jacob, et al.
Publicado: (2021)

Tissue-resident memory T cells in the era of (Neo) adjuvant melanoma management
por: Plunkett, Kai R., et al.
Publicado: (2022)

Anti-PD-L1/PD-L2 therapeutic vaccination in untreated chronic lymphocytic leukemia patients with unmutated IgHV
por: Klausen, Uffe, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_3dvp44ngvmh7sdqqt60fhihs03